Literature DB >> 20452958

Single-nucleotide polymorphisms in the p53 signaling pathway.

Lukasz F Grochola1, Jorge Zeron-Medina, Sophie Mériaux, Gareth L Bond.   

Abstract

The p53 tumor suppressor pathway is central both in reducing cancer frequency in vertebrates and in mediating the response of commonly used cancer therapies. This article aims to summarize and discuss a large body of evidence suggesting that the p53 pathway harbors functional inherited single-nucleotide polymorphisms (SNPs) that affect p53 signaling in cells, resulting in differences in cancer risk and clinical outcome in humans. The insights gained through these studies into how the functional p53 pathway SNPs could help in the tailoring of cancer therapies to the individual are discussed. Moreover, recent work is discussed that suggests that many more functional p53 pathway SNPs are yet to be fully characterized and that a thorough analysis of the functional human genetics of this important tumor suppressor pathway is required.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20452958      PMCID: PMC2857176          DOI: 10.1101/cshperspect.a001032

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  139 in total

1.  Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo.

Authors:  Alexandra Sullivan; Nelofer Syed; Milena Gasco; Daniele Bergamaschi; Giuseppe Trigiante; Marlene Attard; Louise Hiller; Paul J Farrell; Paul Smith; Xin Lu; Tim Crook
Journal:  Oncogene       Date:  2004-04-22       Impact factor: 9.867

2.  Molecular basis for heterogeneity of the human p53 protein.

Authors:  N Harris; E Brill; O Shohat; M Prokocimer; D Wolf; N Arai; V Rotter
Journal:  Mol Cell Biol       Date:  1986-12       Impact factor: 4.272

3.  p53 polymorphic variants at codon 72 exert different effects on cell cycle progression.

Authors:  David Pim; Lawrence Banks
Journal:  Int J Cancer       Date:  2004-01-10       Impact factor: 7.396

4.  The human caspase-8 promoter sustains basal activity through SP1 and ETS-like transcription factors and can be up-regulated by a p53-dependent mechanism.

Authors:  Christian Liedtke; Nadine Groger; Michael P Manns; Christian Trautwein
Journal:  J Biol Chem       Date:  2003-05-14       Impact factor: 5.157

5.  p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer.

Authors:  Ju Won Roh; Jae Weon Kim; Noh Hyun Park; Yong Sang Song; In Ae Park; Sang-Yoon Park; Soon Beom Kang; Hyo Pyo Lee
Journal:  Gynecol Oncol       Date:  2004-05       Impact factor: 5.482

6.  p73 G4C14-to-A4T14 polymorphism and risk of lung cancer.

Authors:  Guojun Li; Li-E Wang; Robert M Chamberlain; Christopher I Amos; Margaret R Spitz; Qingyi Wei
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

7.  Association between p21 codon 31 polymorphism and esophageal cancer risk in a Taiwanese population.

Authors:  Ming-Tsang Wu; Deng-Chyang Wu; Hon-Ki Hsu; Ein-Long Kao; Chien-Hui Yang; Jang-Ming Lee
Journal:  Cancer Lett       Date:  2003-11-25       Impact factor: 8.679

8.  A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer.

Authors:  Bao-li Chang; Siqun L Zheng; Sarah D Isaacs; Kathy E Wiley; Aubrey Turner; Ge Li; Patrick C Walsh; Deborah A Meyers; William B Isaacs; Jianfeng Xu
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

Review 9.  A Ser49Cys variant in the ataxia telangiectasia, mutated, gene that is more common in patients with breast carcinoma compared with population controls.

Authors:  Thomas A Buchholz; Michael M Weil; Cheryl L Ashorn; Eric A Strom; Alice Sigurdson; Melissa Bondy; Ranajit Chakraborty; James D Cox; Marsha D McNeese; Michael D Story
Journal:  Cancer       Date:  2004-04-01       Impact factor: 6.860

10.  Distinct roles for p53, p27Kip1, and p21Cip1 during tumor development.

Authors:  Jeannette Philipp-Staheli; Kyung-Hoon Kim; Denny Liggitt; Kay E Gurley; Gary Longton; Christopher J Kemp
Journal:  Oncogene       Date:  2004-01-29       Impact factor: 9.867

View more
  43 in total

1.  Regulation of p53 stability and function by the deubiquitinating enzyme USP42.

Authors:  Andreas K Hock; Arnaud M Vigneron; Stephanie Carter; Robert L Ludwig; Karen H Vousden
Journal:  EMBO J       Date:  2011-11-15       Impact factor: 11.598

Review 2.  Systems approaches to molecular cancer diagnostics.

Authors:  Shuyi Ma; Cory C Funk; Nathan D Price
Journal:  Discov Med       Date:  2010-12       Impact factor: 2.970

Review 3.  The pharmacogenomics of osteosarcoma.

Authors:  M Serra; C M Hattinger
Journal:  Pharmacogenomics J       Date:  2016-05-31       Impact factor: 3.550

4.  A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma.

Authors:  Karen S Yee; Lukasz Grochola; Garth Hamilton; Anna Grawenda; Elisabeth E Bond; Helge Taubert; Peter Wurl; Gareth L Bond; Eric O'Neill
Journal:  Cancer Res       Date:  2012-03-02       Impact factor: 12.701

Review 5.  Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.

Authors:  Amanda R Wasylishen; Guillermina Lozano
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

Review 6.  Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer.

Authors:  Shanbeh Zienolddiny; Vidar Skaug
Journal:  Lung Cancer (Auckl)       Date:  2011-12-29

7.  Immunorelated gene polymorphisms associated with acute myeloid leukemia.

Authors:  Q Liu; M Hua; S Yan; C Zhang; R Wang; X Yang; F Han; M Hou; D Ma
Journal:  Clin Exp Immunol       Date:  2020-06-02       Impact factor: 4.330

8.  Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.

Authors:  Hongping Yu; Yu-jing Huang; Zhensheng Liu; Li-E Wang; Guojun Li; Erich M Sturgis; David G Johnson; Qingyi Wei
Journal:  Mol Carcinog       Date:  2011-06-07       Impact factor: 4.784

9.  The Role of p16 and MDM2 Gene Polymorphisms in Prolactinoma: MDM2 Gene Polymorphisms May Be Associated with Tumor Shrinkage.

Authors:  Seda Turgut; Muzaffer Ilhan; Saime Turan; Ozcan Karaman; Ilhan Yaylim; Ozlem Kucukhuseyin; Ertugrul Tasan
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

10.  MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.

Authors:  Axel Benner; Larry Mansouri; Davide Rossi; Aneela Majid; Kerstin Willander; Anton Parker; Gareth Bond; Sarka Pavlova; Holger Nückel; Olaf Merkel; Paolo Ghia; Emili Montserrat; Mohd Arifin Kaderi; Richard Rosenquist; Gianluca Gaidano; Martin J S Dyer; Peter Söderkvist; Mats Linderholm; David Oscier; Zuzana Tvaruzkova; Sarka Pospisilova; Ulrich Dührsen; Richard Greil; Hartmut Döhner; Stephan Stilgenbauer; Thorsten Zenz
Journal:  Haematologica       Date:  2014-08       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.